No Data
Calculating The Intrinsic Value Of Liaoning Chengda Biotechnology Co.,Ltd. (SHSE:688739)
Chengda Biotechnology (688739.SH): The application for the production of the trivalent influenza virus split vaccine has been accepted for Pharmaceutical registration.
On March 20, Gelonghui announced that Chengda Biotech (688739.SH) disclosed that its wholly-owned subsidiary, Chengda Biotech (Benxi) Co., Ltd. (referred to as "Benxi Subsidiary"), has recently received the "Acceptance Notice" from the National Medical Products Administration for the domestic production pharmaceutical registration application of the influenza virus split vaccine (referred to as "trivalent influenza vaccine"). The trivalent influenza vaccine produced by the Benxi Subsidiary, which has been accepted for registration, exhibits good safety and immunogenicity, and can stimulate the body to produce immunity against influenza viruses, used for the prevention of influenza caused by vaccine-related strains.
Chengda Biological (688739.SH): The recombinant 15-valent human papillomavirus vaccine (E. coli) has entered the Phase II clinical trial.
On March 19, Gelonghui reported that Chengda Biotechnology (688739.SH) announced that its collaboration with Peking Kangleweishi Biotechnology Co., Ltd. (referred to as "Kangleweishi") on the development of recombinant 15-valent human papillomavirus vaccine (E. coli) (referred to as "this vaccine" or "15-valent HPV vaccine") has completed Phase I clinical trials and will commence Phase II clinical trials. The 15-valent HPV vaccine developed in collaboration with Kangleweishi is currently the highest valency HPV vaccine that has been approved for marketing or IND globally. This vaccine covers all high-risk types of HPV defined by IARC and can reduce cervical
Does Liaoning Chengda Biotechnology Co.,Ltd.'s (SHSE:688739) Weak Fundamentals Mean That The Market Could Correct Its Share Price?
Chengda Biology: Announcement of the 2024 Annual Results Report of Liaoning Chengda Biology Co., Ltd.
Announcement of the 2024 Annual Results Report of Liaoning Chengda Biology Co., Ltd.
Liaoning Chengda Biotechnology Co.,Ltd.'s (SHSE:688739) On An Uptrend But Financial Prospects Look Pretty Weak: Is The Stock Overpriced?
